| Name | Title | Contact Details |
|---|
Brownfield Regional Medical Center is a Brownfield, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gen X International is a Guilford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For more than 25 years, Code Blue Corporation has been the industry leading manufacturer of durable emergency communication solutions. The pioneer in developing and producing vandal-resistant Blue Light Emergency Phones at thousands of education, corporate, hospital, airport and municipal locations around the world, Code Blue’s expansion includes the innovation of advanced public address and mass notification systems to provide a complete end-to-end solution. Founded to address the growing need for sophisticated audio security solutions, Code Blue offers American-made Help Point®, Emergency Signaling, Incident Response and Systems Management products that are innovative, rugged, powerful and easily integrated. Code Blue’s evolution continues with the engineering of new software and hardware designed to meet the ever-changing needs of customers who require an advanced level of incident deterrence that establishes a safe environment. No matter where you go, you can feel safe knowing that there is help at the touch of a button.
Triad Group Inc. is a Hartland, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.